Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5579 - The SENECA study: prognostic role of Serum biomarkErs iN Elderly metastatic Colorectal cAncer patients.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Geriatric Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Camilla Lisanti

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

C. Lisanti1, D. Basile1, S.K. Garattini1, G. Pelizzari1, A. Parnofiello2, F. Cortiula1, E. Ongaro2, M. Cattaneo2, C. Corvaja1, V.J. Andreotti1, M. Bartoletti1, M. Casagrande3, D. Iacono3, M. Bonotto3, P. Ermacora3, N. Pella3, A. Buonadonna4, F. Puglisi5, G. Fasola3, G. Miolo4

Author affiliations

  • 1 Department Of Medicine (dame), University of Udine, 33100 - Udine/IT
  • 2 Department Of Medicine (dame), University of Udine, 33100 - udine/IT
  • 3 Department Of Oncology, ASUIUD Santa Maria della Misericordia, 33100 - Udine/IT
  • 4 Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
  • 5 University Of Udine - Udine, Italy; Department Of Medical Oncology And Cancer Prevention, CRO National Cancer Institute, 33081 - Aviano/IT
More

Resources

Abstract 5579

Background

Aging induces meaningful changes in immune system and inflammation response with increase in monocyte-lymphocyte ratio (MLR) and serum lactate dehydrogenase (LDH) levels. Notably, high levels of these serum biomarkers are associated with poor prognosis in many tumors. We aim to explore the prognostic role of baseline (i.e. before first line chemotherapy) MLR and LDH levels in elderly patients (pts) with metastatic colorectal cancer (MCRC).

Methods

A retrospective analysis of a consecutive cohort of 120 elderly (>70 years) pts treated for MCRC between 2004 and 2017 at the Oncology Department of Aviano National Cancer Institute and University Hospital of Udine (Italy), was conducted. The prognostic role of MLR and LDH levels on overall survival (OS) was investigated through uni- and multivariate Cox regression analyses.

Results

At a median follow-up of 50.83 months, median OS was 19.96 months. Overall, 46 pts (38%) presented a right cancer, 43 pts (36%) a left cancer and 30 pts (25%) a rectal one. In 8 (8%) and 47 (50%) pts a mutation of BRAF or KRAS was detected, respectively. Liver (36%), lymph-nodes (22%), peritoneum (22%) and lung (17%) were the most frequent sites of metastasis. Noteworthy, 22 pts (18%) had undergone a metastasectomy. High levels of LDH (>480 U/L) and MLR (>0.45, obtained with ROC curve) were discovered in 23 (32%) and 51 (42%) patients respectively. By univariate analysis, high levels of LDH (HR 2.81, p = 0.001), MLR (HR 2.26, p < 0.001) or both (HR 6.42, p < 0.001) and node involvement at diagnosis (pN2 vs. pN0 HR 2.15, p = 0.019; pN3 vs. pN0 HR 2.69, p = 0.052) were associated with worse OS. Metastasectomy (HR 0.47, p = 0.009), tumor resection (HR 0.50, p = 0.010) and left sidedness (HR 0.53, p = 0.01) were associated with better OS. By multivariate analysis, high levels of LDH (HR 2.64, p = 0.004), MLR (HR 2.21, p = 0.009) or both (HR 4.19, p = 0.019) were independently associated with worse OS.

Conclusions

High baseline levels of LDH, MLR or both are unfavorable independent prognostic factors in elderly pts treated with first line chemotherapy for MCRC. These preliminary results emphasize the need of prospective studies to validate these cost-effectiveness biomarkers in this subgroup of pts.

Clinical trial identification

Legal entity responsible for the study

University of Udine.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.